{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:01:11Z","timestamp":1792144871161,"version":"4.4.0"},"reference-count":36,"publisher":"Centers for Disease Control MMWR Office","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm7104a1","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T10:41:07Z","timestamp":1643280067000},"page":"109-117","source":"Crossref","is-referenced-by-count":324,"title":["Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2022"],"prefix":"10.15585","volume":"71","author":[{"given":"Miwako","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Gierke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amadea","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Leidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Campos-Outcalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Keipp","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Poehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Pilishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R1","first-page":"1102","article-title":"Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).","volume":"59","author":"CDC","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R2","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"61","author":"CDC","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R3","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R4","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1093\/ofid\/ofab466.215","article-title":"The efficacy and effectiveness of pneumococcal vaccines against pneumococcal pneumonia among adults: a systematic review and meta-analysis.","volume":"8","author":"Childs","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R5","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1093\/ofid\/ofab466.223","article-title":"Systematic review and meta-analysis of pneumococcal vaccine effectiveness against invasive pneumococcal disease among adults.","volume":"8","author":"Farrar","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1473-3099(17)30049-X","article-title":"Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study.","volume":"17","author":"Suzuki","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R7","doi-asserted-by":"publisher","first-page":"e1003326","DOI":"10.1371\/journal.pmed.1003326","article-title":"Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study.","volume":"17","author":"Lawrence","year":"2020","journal-title":"PLoS Med"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R8","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1016\/j.vaccine.2019.04.017","article-title":"Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: a case-control study.","volume":"37","author":"Kim","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R9","unstructured":"VAXNEUVANCE. Package insert. Silver Spring, MD: Food and Drug Administration; 2021. https:\/\/www.fda.gov\/media\/150819\/download"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.vaccine.2019.10.101","article-title":"Rates of hospitalization for community-acquired pneumonia among US adults: a systematic review.","volume":"38","author":"McLaughlin","year":"2020","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R11","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/cid\/ciab375","article-title":"Expanded analysis of 20 pneumococcal serotypes associated with radiographically confirmed community-acquired pneumonia in hospitalized US adults.","volume":"73","author":"Isturiz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R12","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.1016\/j.vaccine.2018.03.012","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-na\u00efve adults \u226550 years of age.","volume":"36","author":"Ermlich","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1080\/21645515.2018.1532250","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults \u226565 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.","volume":"15","author":"Peterson","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.vaccine.2021.08.049","article-title":"A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).","volume":"40","author":"Platt","year":"2022","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R15","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1016\/j.vaccine.2011.05.086","article-title":"The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations.","volume":"29","author":"Said","year":"2011","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R16","unstructured":"Merck Sharp & Dohme Corp. A study to evaluate the safety, tolerability, and immunogenicity of V114 followed by PNEUMOVAX\u212223 in adults at increased risk for pneumococcal disease (V114\u2013017\/PNEU-DAY). Bethesda, MD: US National Library of Medicine; 2021. https:\/\/ClinicalTrials.gov\/show\/NCT03547167"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R17","doi-asserted-by":"crossref","unstructured":"Mohapi L, Pinedo Y, Osiyemi O,  Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV: a randomized phase 3 study. AIDS 2021. Epub November 22, 2021. https:\/\/journals.lww.com\/aidsonline\/Abstract\/9000\/Safety_and_immunogenicity_of_V114,_a_15_valent.96271.aspx","DOI":"10.1097\/QAD.0000000000003126"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R18","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.1016\/j.vaccine.2021.08.038","article-title":"Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged\u202f\u226550\u202fyears: a randomized phase III trial (PNEU-PATH).","volume":"39","author":"Song","year":"2021","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R19","unstructured":"Food and Drug Administration. Summary basis for regulatory action\u2014VAXNEUVANCE. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https:\/\/www.fda.gov\/media\/151201\/download"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R20","unstructured":"PREVNAR 20. Package insert. Silver Spring, MD: Food and Drug Administration; 2021. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/prevnar-20"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R21","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1093\/ofid\/ofaa417.002","article-title":"3. Phase 3 pivotal evaluation of 20-valent pneumococcal conjugate vaccine (PCV20) safety, tolerability, and immunologic noninferiority in participants 18 years and older.","volume":"7","author":"Essink","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R22","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R23","doi-asserted-by":"publisher","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, tolerability, and immunogenicity of a 20\u2013valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age.","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R24","unstructured":"Food and Drug Administration. Summary basis for regulatory action\u2014PREVNAR20. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration, 2021. https:\/\/www.fda.gov\/media\/150388\/download"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1086\/599824","article-title":"Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska Native adults 55\u201370 years of age.","volume":"49","author":"Miernyk","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R26","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1016\/j.vaccine.2013.04.084","article-title":"Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R27","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.vaccine.2014.02.002","article-title":"Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-na\u00efve adults 60\u201364 years of age.","volume":"32","author":"Greenberg","year":"2014","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R28","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1080\/21645515.2021.1888621","article-title":"Sequential administration of Prevnar 13\u2122 and PNEUMOVAX\u2122 23 in healthy participants 50 years of age and older.","volume":"17","author":"Buchwald","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R29","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3899\/jrheum.161407","article-title":"Initial serological response after prime-boost pneumococcal vaccination in rheumatoid arthritis patients: results of a randomized controlled trial.","volume":"44","author":"Nguyen","year":"2017","journal-title":"J Rheumatol"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R30","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: updated recommendations of the Advisory Committee on Immunization Practices.","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R31","doi-asserted-by":"publisher","first-page":"944","DOI":"10.15585\/mmwr.mm6434a4","article-title":"Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"64","author":"Kobayashi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R32","unstructured":"Pfizer. Safety and immunogenicity of 20vPnC coadministered with SIIV in adults \u226565 years of age. Bethesda, MD: US National Library of Medicine; 2020. https:\/\/ClinicalTrials.gov\/show\/NCT04526574"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R33","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1016\/j.vaccine.2017.09.012","article-title":"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults \u226550 years of age: results from a phase III, randomized, non-inferiority trial.","volume":"35","author":"Ofori-Anyinam","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R34","unstructured":"Pfizer. Safety and immunogenicity study of 20vPnC when coadministered with a booster dose of BNT162b2. Bethesda, MD: US National Library of Medicine; 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04887948"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R35","unstructured":"Merck Sharp & Dohme Corp. Safety, tolerability, and immunogenicity of V110 or V114 co-administered with a booster dose of mRNA-1273 in healthy adults (V110-911). Bethesda, MD: US National Library of Medicine; 2021. https:\/\/ClinicalTrials.gov\/show\/NCT05158140"},{"key":"key-10.15585\/mmwr.mm7104a1-202201270927-R36","unstructured":"Food and Drug Administration. PNEUMOVAX23. Package insert. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2020. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/pneumovax-23-pneumococcal-vaccine-polyvalent"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T10:41:12Z","timestamp":1643280072000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7104a1.htm?s_cid=mm7104a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,1,28]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm7104a1","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,28]]},"published":{"date-parts":[[2022,1,28]]}}}